Altretamine

General Toxicity Notes
Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
Excreted Unchanged %
<10
Half-Life (Normalesrd) Hours
7/No data
Plasma Protein Binding %
No data
Volume Of Distribution L/Kg
No data
Dose For Normal Renal Function
150-200 mg/m2
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: No data, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: No data, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable, [D]
References
Damia G, D&#146; Incalci M. Clinical pharmacokinetics of altretamine. Clin Pharmacokinet. 1995; 28: 439-48. [PMID: 7656502] / Lee CR, Faulds D. Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy. Drugs. 1995; 49: 932-53.[PMID: 7641606]
Toxicity Notes
Nephrotoxicity.